Showing 4961-4970 of 6808 results for "".
- Evaxion’s AI-Powered Cancer Vaccine Demonstrates High Response in Early Studyhttps://practicaldermatology.com/news/evaxions-ai-powered-cancer-vaccine-demonstrates-high-efficacy-in-early-study/2467073/Evaxion Biotech A/S, a firm specializing in AI-driven immunology vaccines, recently published data from its Phase 1 dose escalation study of the EVX-01 personalized cancer vaccine for metastatic melanoma showing almost 70% clinical response from patients. The study, published in the J
- Analysis: Few Dermatologists Share Sun Protection Advice on TikTokhttps://practicaldermatology.com/news/analysis-few-dermatologists-share-sun-protection-advice-tiktok/2467072/A new analysis in the Journal of Drugs in Dermatology shows a significant gap in the presence of board-certified dermatologists (BCDs) on TikTok, particularly concerning sun protection content. "Limited studies have analyzed sources of TikTok videos associated with sun safety and
- Study: Advanced AI Enhances Melanoma Detectionhttps://practicaldermatology.com/news/study-advanced-ai-enhances-melanoma-detection/2467071/A new study suggests a novel deep-learning model based on diagnostic data may help harness the power of neural networks and artificial intelligence (AI) to more accurately diagnose melanoma.
- Adtralza Pre-Filled Pen Now Available for Canadian Atopic Dermatitis Patientshttps://practicaldermatology.com/news/adtralza-pre-filled-pen-now-available-canadian-atopic-dermatitis-patients/2467019/A new Adtralza® (tralokinumab injection) pre-filled pen has been made available for the first time in Canada for the treatment of moderate-to-severe atopic dermatitis (AD), according to a press announcement from LEO Pharma Inc. The single-use 2 mL pre-filled pen "simplifies the
- More Positive Upadacitinib Data Presentedhttps://practicaldermatology.com/news/more-positive-upadacitinib-data-presented/2467018/New data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from June 8-10 in Chicago, Illinois, built on previously published top-line results comparing upadacitinib to dupilumab by demonstrating superiority for all ranked secondary endpoints at varying response levels and time
- Roflumilast Cream 0.3% Improves Patient-Reported Outcomes in Psoriasis: Analysishttps://practicaldermatology.com/news/patient-reported-outcomes-improve-roflumilast-cream-03-psoriasis/2466998/A recent study suggested efficacy for roflumilast cream 0.3% for the topical treatment of plaque psoriasis. Researchers for the study pooled data from two Phase 3 clinical trials (DERMIS-1 and DERMIS-2), which included patients aged ≥2 years with plaque psoriasis affecting between 2% and
- FDA Approves First Eyedrops to Treat Mites Living on Eyelasheshttps://practicaldermatology.com/news/fda-approves-first-eyedrops-treat-mites-living-eyelashes/2466993/FDA Approves First Eyedrops to Treat Mites Living on Eyelashes More than 25 million Americans are living with Demodex blepharitis, an underdiagnosed condition that involves mites living on a person’s eyelashes. Demodex blepharitis has gone underdiagnosed for decades because of a l
- Analysis: Deucravacitinib Shows Sustained Efficacy and Safety Over Four Yearshttps://practicaldermatology.com/news/analysis-deucravacitinib-shows-sustained-efficacy-and-safety-over-four-years/2466961/A new analysis suggested that deucravacitinib showed acceptable safety and efficacy over the course of 4 years of treatment. The POETYK PSO-1 and PSO-2 trials, upon which the analysis was based, randomized patients in (1:2:1) to receive placebo, deucravacitinib 6 mg once daily (QD), or a
- Study Highlights Gaps in Dermatology PA Certification Exam Coveragehttps://practicaldermatology.com/news/research-highlights-gaps-dermatology-pa-certification-exam-coverage/2466960/New research suggests that the prevalence of skin disease burden in the United States generally aligns with the physician assistant (PA) certification exam, with areas for improvement. According to the new study published in the Journal of Dermatology Physicians Assistants, the National C
- Rinvoq Now Available for Pediatric Patients with Psoriatic Arthritis and Polyarticular Juvenile Idiopathic Arthritishttps://practicaldermatology.com/news/rinvoq-now-available-pediatric-patients-psoriatic-arthritis-and-polyarticular-juvenile-idiopathic-arthritis/2466955/AbbVie announced that its blockbuster drug Rinvoq (upadacitinib) is now indicated in the US for the treatment of pediatric patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA). The medication is indicated for those who had